Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/33172
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCassano, M-
dc.contributor.authorDellavalle, A-
dc.contributor.authorTedesco, FS-
dc.contributor.authorQuattrocelli, M-
dc.contributor.authorCrippa, S-
dc.contributor.authorRonzoni, F-
dc.contributor.authorSalvade, A-
dc.contributor.authorBERARDI, Emanuele-
dc.contributor.authorTorrente, Y-
dc.contributor.authorCossu, G-
dc.contributor.authorSampaolesi, M-
dc.date.accessioned2021-01-25T15:16:54Z-
dc.date.available2021-01-25T15:16:54Z-
dc.date.issued2011-
dc.date.submitted2021-01-19T18:31:35Z-
dc.identifier.citationDEVELOPMENT, 138 (20) , p. 4523 -4533-
dc.identifier.urihttp://hdl.handle.net/1942/33172-
dc.description.abstractMice deficient in α-sarcoglycan (Sgca-null mice) develop progressive muscular dystrophy and serve as a model for human limb girdle muscular dystrophy type 2D. Sgca-null mice suffer a more severe myopathy than that of mdx mice, the model for Duchenne muscular dystrophy. This is the opposite of what is observed in humans and the reason for this is unknown. In an attempt to understand the cellular basis of this severe muscular dystrophy, we isolated clonal populations of myogenic progenitor cells (MPCs), the resident postnatal muscle progenitors of dystrophic and wild-type mice. MPCs from Sgca-null mice generated much smaller clones than MPCs from wild-type or mdx dystrophic mice. Impaired proliferation of Sgca-null myogenic precursors was confirmed by single fiber analysis and this difference correlated with Sgca expression during MPC proliferation. In the absence of dystrophin and associated proteins, which are only expressed after differentiation, SGCA complexes with and stabilizes FGFR1. Deficiency of Sgca leads to an absence of FGFR1 expression at the membrane and impaired MPC proliferation in response to bFGF. The low proliferation rate of Sgca-null MPCs was rescued by transduction with Sgca-expressing lentiviral vectors. When transplanted into dystrophic muscle, Sgca-null MPCs exhibited reduced engraftment. The reduced proliferative ability of Sgca-null MPCs explains, at least in part, the severity of this muscular dystrophy and also why wild-type donor progenitor cells engraft efficiently and consequently ameliorate disease.-
dc.description.abstractMice deficient in alpha-sarcoglycan (Sgca-null mice) develop progressive muscular dystrophy and serve as a model for human limb girdle muscular dystrophy type 2D. Sgca-null mice suffer a more severe myopathy than that of mdx mice, the model for Duchenne muscular dystrophy. This is the opposite of what is observed in humans and the reason for this is unknown. In an attempt to understand the cellular basis of this severe muscular dystrophy, we isolated clonal populations of myogenic progenitor cells (MPCs), the resident postnatal muscle progenitors of dystrophic and wild-type mice. MPCs from Sgca-null mice generated much smaller clones than MPCs from wild-type or mdx dystrophic mice. Impaired proliferation of Sgca-null myogenic precursors was confirmed by single fiber analysis and this difference correlated with Sgca expression during MPC proliferation. In the absence of dystrophin and associated proteins, which are only expressed after differentiation, SGCA complexes with and stabilizes FGFR1. Deficiency of Sgca leads to an absence of FGFR1 expression at the membrane and impaired MPC proliferation in response to bFGF. The low proliferation rate of Sgca-null MPCs was rescued by transduction with Sgca-expressing lentiviral vectors. When transplanted into dystrophic muscle, Sgca-null MPCs exhibited reduced engraftment. The reduced proliferative ability of Sgca-null MPCs explains, at least in part, the severity of this muscular dystrophy and also why wild-type donor progenitor cells engraft efficiently and consequently ameliorate disease.-
dc.description.sponsorshipFunding This work was supported in part by FWO-Odysseus Program Grant No. G.0907.08; Research Council of the University of Leuven, Grant No. OT/09/053 and EME-C2161-GOA/11/012; Wicka Charity Funds, USA, Grant No. zkb8720; the Italian Ministry of University and Scientific Research Grant No. 2005067555_003, PRIN 2006-08, CARIPLO 2007.5639 and 2005.2008; EC FP7 CARE-MI No. 242038; and Optistem No. 223098. Acknowledgements We thank Gianpaolo Papaccio for critical discussion of the manuscript; K. P. Campbell for providing Sgca-null mice; Laura Perani, Rossana Tonlorenzi and Rudi Micheletti for technical assistance; Christina Vochten for professional secretarial service; Paolo Luban for a kind donation; Dr Shea Carter for manuscript editing; and Dr Maurizio Moggio (Bank of DNA, Cell Lines and Nerve-Muscle-Cardiac Tissues/Telethon Genetic BioBank Network, Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy) for providing the LGMD2D sample-
dc.language.isoen-
dc.publisherCOMPANY OF BIOLOGISTS LTD-
dc.rights2011. Published by The Company of Biologists Ltd-
dc.subject.otherMyogenic progenitor cells-
dc.subject.otherLimb girdle muscular dystrophy-
dc.subject.otherCell therapy-
dc.subject.otherMouse-
dc.titleAlpha sarcoglycan is required for FGF-dependent myogenic progenitor cell proliferation in vitro and in vivo-
dc.typeJournal Contribution-
dc.identifier.epage4533-
dc.identifier.issue20-
dc.identifier.spage4523-
dc.identifier.volume138-
local.bibliographicCitation.jcatA1-
local.publisher.placeBIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1242/dev.070706-
dc.identifier.pmid21903674-
dc.identifier.isiWOS:000295085600019-
dc.identifier.urlhttps://doi.org/10.1242/dev.070706-
dc.contributor.orcid0000-0002-0775-9605-
local.provider.typeOrcid-
local.uhasselt.uhpubyes-
local.uhasselt.internationalyes-
item.fullcitationCassano, M; Dellavalle, A; Tedesco, FS; Quattrocelli, M; Crippa, S; Ronzoni, F; Salvade, A; BERARDI, Emanuele; Torrente, Y; Cossu, G & Sampaolesi, M (2011) Alpha sarcoglycan is required for FGF-dependent myogenic progenitor cell proliferation in vitro and in vivo. In: DEVELOPMENT, 138 (20) , p. 4523 -4533.-
item.fulltextWith Fulltext-
item.contributorCassano, M-
item.contributorDellavalle, A-
item.contributorTedesco, FS-
item.contributorQuattrocelli, M-
item.contributorCrippa, S-
item.contributorRonzoni, F-
item.contributorSalvade, A-
item.contributorBERARDI, Emanuele-
item.contributorTorrente, Y-
item.contributorCossu, G-
item.contributorSampaolesi, M-
item.accessRightsOpen Access-
crisitem.journal.issn0950-1991-
crisitem.journal.eissn1477-9129-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
4523.full.pdfPublished version2.72 MBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

27
checked on Feb 16, 2026

WEB OF SCIENCETM
Citations

24
checked on Feb 18, 2026

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.